Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes

Biochemical and Biophysical Research Communications

Volumn 272, Issue 1, 2000, Pages 18-22

  Ohta, Mitsuhiro ^a,b   Mizuta, Ikuko ^a,c   Ohta, Kiyoe ^a   Nishimura, Masataka ^a   Mizuta, Eiji ^a   Hayashi, Kyozo ^d   Kuno, Sadako ^a  

^a UTANO NATIONAL HOSPITAL   (Japan)

^b KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^c Japan Foundation for Aging and Health   (Japan)

^d GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Apomorphine; Astrocytes; BDNF; Dopamine agonist; GDNF; Neuroprotection; NGF; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; APOMORPHINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA; NERVE GROWTH FACTOR;

ANIMAL CELL; ARTICLE; ASTROCYTE; CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; MESSENGER RNA SYNTHESIS; MOUSE; NEUROPROTECTION; NEWBORN; NONHUMAN; NORTHERN BLOTTING; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALIA;

EID: 0034720454     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2000.2732     Document Type: Article

References (25)

1. Jankovic, J., and Marsden, D. (1998) Therapeutic strategies in Parkinson's disease. In Parkinson's Disease and Movement Disorders (3rd ed.) (Jankovic, J., and Tolosa, E., Eds.), pp. 191-220, Williams & Wilkins, Baltimore, MD.
2. Gerlach, M., Riederer, P., and Youdim, M. B. H. (1996) Molecular mechanisms for neurodegeneration: Synergism between reactive oxygen species, calcium, and excitotoxic amino acids. Adv. Neurol. 69, 177-194.
3. Ogawa, N., Edamatsu, R., Mizukawa, K., Asanuma, M., Kohno, M., and Mori, A. (1993) Degeneration of dopaminergic neurons and free radicals: Possible participation of levodopa. Adv. Neurol. 60, 242-250.
4. Yoshikawa, T. (1993) Free radicals and their scavengers in Parkinson's disease. Eur. Neurol. 33(Suppl 1), 60-68.
5. Olanow, C. W., Jenner, P., and Brooks, D. (1998) Dopamine agonists and neuroprotection in Parkinson's disease. Ann. Neurol. 44(Suppl 1), 167-174.
6. Shults, C. W. (1998) Neurotrophic factors in neurodegenerative disorders. In Parkinson's Disease and Movement Disorders (3rd ed.) (Jankovic, J., and Tolosa, E., Eds.), pp. 105-118, Williams & Wilkins, Baltimore, MD.
7. Gash, D. M., Zhang, Z., and Gerhardt, G. (1998) Neuroprotective and neurorestorative properties of GDNF. Ann. Neurol. 44(Suppl 1), 121-125.
8. Kordower, J. H., Palfi, S., Chen, E.-Y., Ma, S. Y., Sendera, T., Cochran, E. J., Mufson, E. J., Penn, R., Goetz, C. G., and Comelia, C. D. (1999) Clinicopathological findings following intraventricular glial-derived neurotrophic factor in a patient with Parkinson's disease. Ann. Neurol. 46, 419-424.
9. Mogi, M., Togari, A., Kondo, T., Mizuno, Y., Komure, O., Kuno, S., Ichinose, H., and Nagatsu, T. (1999) Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci. Lett. 270, 45-48.
10. Tooyama, I., Kawamata, T., Walker, D., Yamada, T., Hanai, K., Kimura, H., Iwane, M., Igarashi, K., McGeer, E. G., and McGeer, P. L. (1993) Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease. Neurology 43, 372-376.
11. Furukawa, S., Furukawa, Y., Satoyoshi, E., and Hayashi, K. (1987) Regulation of nerve growth factor synthesis/secretion by catecholamine in cultured mouse astroglial cells. Biochem. Biophys. Res. Commun. 147, 1048-1054.
12. Furukawa, Y., Tomioka, N., Sato, W., Satoyoshi, E., Hayashi, K., and Furukawa, S. (1989) Catecholamines increase nerve growth factor mRNA content in both mouse astroglial cells and fibroblast cells. FEBS Lett. 247, 463-467.
13. Furukawa, S., Furukawa, Y., Satoyoshi, E., and Hayashi, K. (1986) Synthesis and secretion of nerve growth factor by mouse astroglial cells in culture. Biochem. Biophys. Res. Commun. 136, 57-63.
14. Murase, K., Takeuchi, R., Furukawa, S., and Hayashi, K. (1990) Highly sensitive enzyme immunoassay for β-nerve growth factor (NGF): A tool for measurement of NGF in rat serum. Biochem. Int. 22, 807-813.
15. Selby, M. J., Edwards, R., Sharp, F., and Rutter, W. J. (1987) Mouse nerve growth factor gene: Structure and expression. Mol. Cell. Biol. 7, 3057-3064.
16. Watabe, K., Fukuda, T., Tanaka, J., Honda, H., Toyohara, K., and Sakai, O. (1995) Spontaneously immortalized adult mouse Schwann cells secrete autocrine and paracrine growth-promoting activities. J. Neurosci. Res. 41, 279-290.
17. Sabath, D. E., Broome, H. E., and Prystowsky, M. B. (1990) Glyceraldehyde-3-phosphate dehydrogenase mRNA is a major interleukin 2-induced transcript in a cloned T-helper lymphocyte. Gene 91, 185-191.
18. Kokame, K., Kato, H., and Miyata, T. (1996) Homocysteine-respondent genes in vascular endothelial cells identified by differential display analysis. J. Biol. Chem. 271, 29659-29665.
19. Müller, H. W., Junghans, U., and Kappler, J. (1995) Astroglial neurotrophic and neurite-promoting factors. Pharmac. Ther. 65, 1-18.
20. Furukawa, Y., Furukawa, S., Omae, H., Awatsuji, H., and Hayashi, K. (1993) Alkylcatechols regulate NGF gene expression in astroglial cells via both protein kinase C and cAMP-independent mechanisms. J. Neurosci. Res. 35, 522-529.
21. Hill, P., Lai, Y., Hnilo, J., Lin, C.-C., Karla, M., Bounds, S., Herz, J., and Michell, R. (1996) Cloning, expression, and comparison of the binding characteristics of the known human dopamine receptors. Adv. Neurol. 69, 41-52.
22. Lindsay, R. M., Altar, C. A., Cedarbaum, J. M., Hyman, C., and Wiegand, S. J. (1993) The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease. Exp. Neurol. 124, 103-118, doi:10.1006/exnr.1993.1181.
23. Rohrer, D. C., Nilaver, G., Nipper, V., and Machida, C. A. (1996) Genetically modified PC12 brain grafts: Survivability and inducible nerve growth factor expression. Cell Transplant. 5, 57-68.
24. Winn, S. R., Tresco, P. A., Zielinski, B., Sagen, J., and Aebischer, P. (1992) Microencapsulated bovine chromaffin cells in vitro: Effect of density and coseeding with a NGF-releasing cell line. J. Neural Transplant. Plast. 3, 115-124.
25. 2 and 6-hydroxy-dopamine. Mov. Disord. 13, 242-248.